Literature DB >> 32052386

Comparison of Magnetic Resonance Imaging and Contrast-Enhanced Ultrasound as Diagnostic Options for Unclear Cystic Renal Lesions: A Cost-Effectiveness Analysis.

Felix Gassert1, Moritz Schnitzer2, Su Hwan Kim3, Wolfgang G Kunz3, Benjamin Philipp Ernst4, Dirk-André Clevert5, Dominik Nörenberg6, Johannes Rübenthaler2, Matthias Frank Froelich6.   

Abstract

PURPOSE: Correct differentiation between malignant and benign incidentally found cystic renal lesions has critical implications for patient management. In several studies contrast-enhanced ultrasound (CEUS) showed higher sensitivity with respect to the accurate characterization of these lesions compared to MRI, but the cost-effectiveness of CEUS has yet to be investigated. The aim of this study was to analyze the cost-effectiveness of CEUS as an alternative imaging method to MRI for the characterization of incidentally found cystic renal lesions.
MATERIALS AND METHODS: A decision model including the diagnostic modalities MRI and CEUS was created based on Markov simulations estimating lifetime costs and quality-adjusted life years (QALYs). The recent literature was reviewed to obtain model input parameters. The deterministic sensitivity of diagnostic parameters and costs was determined and probabilistic sensitivity analysis using Monte-Carlo Modelling was applied. Willingness-to-pay (WTP) was assumed to be $ 100 000/QALY.
RESULTS: In the base-case scenario, the total costs for CEUS were $9654.43, whereas the total costs for MRI were $9675.03. CEUS resulted in an expected effectiveness of 8.06 QALYs versus 8.06 QALYs for MRI. Therefore, from an economic point of view, CEUS was identified as an adequate diagnostic alternative to MRI. Sensitivity analysis showed that results may vary if CEUS costs increase or those of MRI decrease.
CONCLUSION: Based on the results of the analysis, the use of CEUS was identified as a cost-effective diagnostic strategy for the characterization of incidentally found cystic renal lesions. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32052386     DOI: 10.1055/a-1110-7172

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  5 in total

1.  Diagnostic Workup for Patients with Solid Renal Masses: A Cost-Effectiveness Analysis.

Authors:  Jasmin Runtemund; Johannes Rübenthaler; Niklas von Münchhausen; Maria Ingenerf; Freba Grawe; Gloria Biechele; Felix Gerhard Gassert; Fabian Tollens; Johann Rink; Sasa Cecatka; Christine Schmid-Tannwald; Matthias F Froelich; Dirk-André Clevert; Moritz L Schnitzer
Journal:  Cancers (Basel)       Date:  2022-04-29       Impact factor: 6.575

2.  Diagnostic Performance of Contrast-Enhanced Ultrasound (CEUS) in the Evaluation of Solid Renal Masses.

Authors:  Thomas Geyer; Vincent Schwarze; Constantin Marschner; Moritz L Schnitzer; Matthias F Froelich; Johannes Rübenthaler; Dirk-André Clevert
Journal:  Medicina (Kaunas)       Date:  2020-11-19       Impact factor: 2.430

3.  Contrast-enhanced Ultrasound (CEUS) vs contrast-enhanced computed tomography for multilocular cystic renal neoplasm of low malignant potential: A retrospective analysis for diagnostic performance study.

Authors:  Kun Shan; A Bu DU Li Ai Ze Zi Ha Li Fu; Ningning Liu; Qiliang Cai; Qingfeng Fu; Leyi Liu; Xiaoyu Sun; Zhihong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.889

4.  Contrast-Enhanced Ultrasound for Assessing Abdominal Conditions in Pregnancy.

Authors:  Thomas Geyer; Johannes Rübenthaler; Matthias F Froelich; Laura Sabel; Constantin Marschner; Vincent Schwarze; Dirk-André Clevert
Journal:  Medicina (Kaunas)       Date:  2020-12-08       Impact factor: 2.430

5.  Contrast-Enhanced Ultrasound (CEUS) for the Evaluation of Bosniak III Complex Renal Cystic Lesions-A 10-Year Specialized European Single-Center Experience with Histopathological Validation.

Authors:  Vincent Schwarze; Johannes Rübenthaler; Saša Čečatka; Constantin Marschner; Matthias Frank Froelich; Bastian Oliver Sabel; Michael Staehler; Thomas Knösel; Thomas Geyer; Dirk-André Clevert
Journal:  Medicina (Kaunas)       Date:  2020-12-12       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.